A Hidden Protein-Folding Fault That Drives Diabetes

Imagine a factory where every part must be bent, clipped and checked to fit. One warped piece can slow the line, then stop it. In pancreatic beta cells, proinsulin is that part. When its folding goes wrong, the cell stumbles, and the organ that keeps our blood sugar in check begins to fail.

Scientists from Sanford Burnham Prebys and the University of Michigan have traced an intimate partnership inside beta cells that helps proinsulin reach its final, functional shape. Their work, published in the Proceedings of the National Academy of Sciences, points to a fragile choreography of molecular helpers. When that choreography breaks down, misfolded proinsulin accumulates and stresses the cell, pushing it closer to the dysfunction that underlies type 2 diabetes.

Scientists have uncovered a protein-folding partnership that helps insulin-producing cells manage proinsulin. Its breakdown may reveal an overlooked driver of beta cell failure in diabetes. 

When folding goes wrong inside beta cells

Proteins do not arrive ready-made. They emerge as chains of amino acids and must fold into precise three-dimensional structures to work. That folding happens in the endoplasmic reticulum, a cellular compartment that behaves like a quality-control workshop. Chaperone proteins supervise the process, preventing mistakes and shepherding correct folds along the assembly line.

One of those chaperones, binding immunoglobulin protein or BiP, has long been known as a key guardian of proinsulin. But BiP does not act alone. The new study reveals that cochaperones—proteins that assist chaperones—are essential in the same way that a doubles partner is essential in tennis. Remove the partner and the team loses its edge.

Randal J. Kaufman, PhD, is a professor in the Center for Metabolic and Liver Diseases at Sanford Burnham Prebys.

The researchers used a clever molecular tag to map BiP's companions. By genetically engineering mice so BiP carried a small 3xFLAG peptide in beta cells, they could pull BiP from cell extracts and identify the proteins bound to it. That approach turned up a crucial collaborator: p58IPK, a cochaperone whose absence produced striking defects.

Cells and mice lacking p58IPK accumulated more misfolded proinsulin and produced less mature insulin. Restoring p58IPK in modified cells repaired folding, improved transport of proinsulin through the secretory pathway, and reduced the buildup of defective molecules. But p58IPK is not a replacement for BiP. If BiP is gone, p58IPK cannot carry the load. Likewise, adding more BiP when p58IPK is absent yields only limited benefit. The lesson is clear: proinsulin folding depends on a coordinated team, not a solo star.

A molecular tag makes hidden partners visible

Why does this matter for diabetes? In type 2 diabetes, beta cells are exposed to chronic metabolic stress. That stress burden can disrupt folding and increase misfolded proinsulin. Misfolded proteins are toxic when they pile up. They trigger endoplasmic reticulum stress, activate cellular alarm systems, and eventually contribute to beta cell dysfunction and loss. The new findings place BiP and its cochaperones squarely in that sequence of events.

Insook Jang, PhD, is a staff scientist in the Kaufman lab at Sanford Burnham Prebys.

The study also cataloged additional proteins that join the proinsulin folding pathway, including factors involved in transport, quality control and removal of defects. Each of those partners is a potential point of vulnerability. Each is also a possible therapeutic target. If scientists can stabilize the network that maintains proinsulin shape, they may be able to protect beta cells early in disease progression.

Current diabetes medicines typically focus on symptoms: boosting insulin secretion, increasing insulin sensitivity in tissues, or lowering blood glucose by other metabolic routes. Very few treatments aim to preserve the beta cell's internal machinery. That may be a missed opportunity. Could drugs that enhance BiP-cochaperone coordination, or small molecules that act as chemical chaperones, slow or prevent the decline of insulin-producing cells?

Speculative approaches already under discussion include small molecules that boost chaperone activity, gene therapy to raise levels of protective cochaperones, and targeted delivery of folding helpers to beta cells. Each idea faces obstacles. Delivering treatments specifically to pancreatic islets is difficult. Long-term effects must be safety tested. But the concept expands the therapeutic landscape beyond glucose control and toward maintaining cellular resilience.

Expert Insight

"This work reframes how we think about beta cell failure," says Dr. Elena Torres, an endocrinologist and researcher who studies cellular stress in metabolic disease. "Instead of treating high blood sugar alone, we should ask whether the cell’s folding workshop can be reinforced. Targeting chaperone networks could complement existing therapies and preserve insulin production for longer."

That view captures both promise and caution. Strengthening protein folding could reduce the toxic buildup of misfolded proteins and blunt the cascade that leads to cell death. But intervening in fundamental cellular processes requires precision. Too much or misdirected chaperone activity could have unintended consequences. The next step will be detailed mapping of each partner's role, timing and regulatory cues.

Conclusion

The discovery that BiP and the cochaperone p58IPK collaborate to maintain proinsulin folding gives researchers a new angle on why beta cells fail in diabetes. It shifts some of the focus away from symptoms and toward cellular mechanics. Strengthening the folding machinery may be a strategy to protect insulin-producing cells, but translating that idea into safe, effective therapies will require careful work. For now, the study reminds us that sometimes the smallest molecular partnerships determine the fate of whole organs.